| HOME >> BIOLOGY >> TECHNOLOGY |
Poster Discussion, Monday June 1, 2:00 pm to 6:00 pm, Level 3, W340A
Discussion, Monday June 1, 5:00 pm to 6:00 pm, Level 2, West Hall F3
Authors: C. N. Krasner, A. Poveda, T. Herzog, J. Vermorken, B. Monk, P. Zintl, J. Li, Y. Su, R. Dhawan, S. Kaye; Massachusetts General Hospital, Boston, MA; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain;
About DOXIL(R) (doxorubicin HCl liposome injection)
DOXIL is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum based therapy. DOXIL in combination with VELCADE(R) (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.
IMPORTANT SAFETY INFORMATION
BOXED WARNINGS:
Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution
| SOURCE Centocor Ortho Biotech Products, L.P. Copyright©2009 PR Newswire. All rights reserved |